Addex Pharmaceuticals (SWISS: ADXN), the allosteric modulation company, announced the start of a Phase IIb trial of ADX10059 monotherapy in patients with gastroesophageal reflux disease (GERD), the cause of heartburn and other symptoms. ADX10059 is a first-in- class reflux inhibitor that works by reducing activation of the metabotropic glutamate receptor 5 (mGluR5) through negative allosteric modulation (NAM).

Addex Pharmaceuticals (SWISS: ADXN), the allosteric modulation company, announced the start of a Phase IIb trial of ADX10059 monotherapy in patients with gastroesophageal reflux disease (GERD), the cause of heartburn and other symptoms. ADX10059 is a first-in- class reflux inhibitor that works by reducing activation of the metabotropic glutamate receptor 5 (mGluR5) through negative allosteric modulation (NAM).

Researchers at the University of Pennsylvania School of Medicine have discovered stem cells in the esophagus of mice that were able to grow into tissue-like structures and when placed into immune-deficient mice were able to form parts of an esophagus lining. The investigators report their findings online this month in the Journal of Clinical Investigation.

MEN WITH EMPHYSEMA AT RISK FOR OSTEOPOROSIS New research shows that men with chronic obstructive pulmonary disease (COPD), which includes emphysema and chronic bronchitis, may also be at risk for osteoporosis. Researchers from Japan performed chest CT scans and pulmonary function tests on 65 male patients with COPD.

MEN WITH EMPHYSEMA AT RISK FOR OSTEOPOROSIS New research shows that men with chronic obstructive pulmonary disease (COPD), which includes emphysema and chronic bronchitis, may also be at risk for osteoporosis. Researchers from Japan performed chest CT scans and pulmonary function tests on 65 male patients with COPD.